The Promise Study: How a Blood Test Can Detect, Intercept, and Potentially Eliminate Cancer

To significantly reduce the burden of cancer, we must advance our ability to detect and prevent cancers and their precursor conditions at their earliest stages. Listen to a conversation with Dana-Farber’s Irene Ghobrial, MD, lead investigator on The Promise Study, to learn how this groundbreaking research initiative is screening those at high risk for multiple myeloma early in order to identify ways to stop cancer before it starts.

To learn more, visit the Revolutionary Science section of this site.

Give Now

Thank you for your interest in learning more about The Dana-Farber Campaign. You have been added to our email list and will receive updates on ways to join us in defying cancer. You can unsubscribe at any time.

There has been an issue submitting your request. Please try again.

Founded in Boston in 1947, Dana-Farber is a principal teaching affiliate of Harvard Medical School and a federally designated Comprehensive Cancer Center that develops and disseminates innovative patient therapies and scientific discoveries throughout the world. About Our Patient Stories: Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.

At Dana-Farber we are committed to an inclusive community where human differences are valued and celebrated, and where all are welcome. We work every day to create an innovative, caring, and inclusive environment where each patient, family, and staff member feels valued and respected.